IRUS-ANZ has moved. From January 2022, new monthly statistics will only be added to the IRUS R5 service. This site is archived. All statistics up to December 2021 will remain available on this site.

Item Statistics

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

RepositoryUniversity of Queensland [UQ eSpace]
URLhttps://espace.library.uq.edu.au/view/UQ:287651
Author(s)Cohen, Jeffrey A.; Coles, Alasdair J.; Arnold, Douglas L.; Confavreux, Christian; Fox, Edward J.; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W.; Weiner, Howard L.; Fisher, Elizabeth; Brinar, Vesna V.; Giovannoni, Gavin; Stojanovic, Miroslav; Er
Item typeArticle
JournalLancet, The, Print_ISSN:0140-6736
DOIhttps://doi.org/10.1016/S0140-6736(12)61769-3

Sorry - we've not seen any usage for this item in the last six weeks...

Jisc logo Cranfield logo CAVAL logo